• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Immediate vs Extended-Release Quetiapine for Schizophrenia
Research Update

Immediate vs Extended-Release Quetiapine for Schizophrenia

January 1, 2024
Richard Moldawsky, MD
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Richard Moldawsky, MD. Dr. Moldawsky has no financial relationships with companies related to this material.

Getting your Trinity Audio player ready...

REVIEW OF: Terao I et al, J Psychopharmacology2023;37(10);953–959

STUDY TYPE: Meta-analysis

Quetiapine is widely used in varying doses and formulations to manage schizophrenia. Given its extensive dose range in both immediate-release (IR) and extended-release (ER) forms, it can be challenging to determine which formulation is most appropriate to prescribe. This research offers a valuable comparison of IR and ER quetiapine across different dosages.

The study synthesized data from six double-blind, randomized, placebo-controlled trials involving 2,456 patients using a dose-response network meta-analysis. This analytical tool allows researchers to evaluate multiple doses within the same analysis, avoiding common issues found in traditional meta-analyses that mix different doses. The main outcomes were scores on the Positive and Negative Syndrome Scale and/or the Brief Psychiatric Rating Scale.

Both IR and ER quetiapine were more effective than placebo, which was not a surprise. However, there were significant differences across formulations and doses. IR quetiapine had a bell-shaped dose-response curve up to 500 mg, which peaked at a maximally effective dose of about 300 mg. ER quetiapine only had increasing efficacy above 300 mg, increasing linearly to a maximally effective dose around 550 mg and then decreasing somewhat to 800 mg (the highest dose studied). Superimposing these dose-response curves showed IR significantly outperforming ER at doses between 100 and 300 mg, with ER better in the 600–700 mg range.

The authors summarized their findings on quetiapine for schizophrenia with the following recommendations:

  • Begin with an IR formulation for doses up to 300 mg.
  • If the clinical response at 300 mg of IR is inadequate, switch to ER to titrate further. 

CARLAT TAKE

This meta-analysis provides us with some updated recommendations for prescribing quetiapine for schizophrenia. It suggests using IR quetiapine for doses up to 300 mg. For higher doses, ER is likely more effective, but may have diminishing returns above 550 mg.

General Psychiatry
KEYWORDS dose response quetiapine schizophrenia
    Richard Moldawsky, MD

    Buprenorphine versus Methadone for Prescription Opioid Use Disorder

    More from this author
    www.thecarlatreport.com
    Issue Date: January 1, 2025
    SUBSCRIBE NOW
    Table Of Contents
    Learning Objectives, Adult ADHD, TCPR, January 2025
    How to Diagnose Borderline Personality Disorder
    ADHD: Beyond Stimulants
    Immediate vs Extended-Release Quetiapine for Schizophrenia
    Strategies to Reduce Antipsychotic-Induced Hyperprolactinemia
    Cariprazine Augmentation for MDD
    CME Post-Test, Adult ADHD, TCPR, January 2025
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.